Clinical Trials Browser

Phase 3 × Alzheimer Disease × 90 days × Clear all

NCT05894954 2026-02-18

EVANTHEA

Phase 3 Completed

Alzheimer Disease, Anomia, Dementia, Lymphoma, Follicular, Cognitive Dysfunction